SCHEMBL3192134

SCHEMBL3192134

O=C1C=C(C2CCCC2)OS(=O)(=O)N1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 1/20 0.47
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
DAO P14920 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acesulfame SCHEMBL3551 0.65 CA9 (1.00) CA9
Acesulfame SCHEMBL7594675 0.65 CA9 (1.00) CA9
SCHEMBL3188444 0.63 CA9 (0.34) CA9
SCHEMBL3180652 0.63 CA9 (0.34) CA9
Acesulfame SCHEMBL328775 0.63 CA9 (0.96) CA9
Acesulfame SCHEMBL7568032 0.63 CA9 (0.96) CA9
Acesulfame SCHEMBL17766790 0.63 CA9 (0.96) CA9
Acesulfame SCHEMBL17350249 0.63 CA9 (0.96) CA9
Acesulfame SCHEMBL3126570 0.63 CA9 (0.96) CA9
Acesulfame SCHEMBL38654964 0.63 CA9 (0.96) CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662957-B2 Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2010-02-16 US disclosed
US-20090318685-A1 METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2009-12-24 US disclosed
US-7408059-B2 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide; cyclizing a beta-ketoamide-N-sulfonic acid with an acid anhydride DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2008-08-05 US disclosed
US-20050182255-A1 Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof DAICEL CHEMICAL INDUSTRIES, LTD. 2005-08-18 US disclosed
EP-1564211-A1 Method for producing 3,4-Dihydro-1,2,3-Oxathiazin-4-one-2,2-Dioxide compound or salt thereof Daicel Chemical Industries, Ltd. (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182255-A1 Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof CA2, HAO2, SRD5A2 CA9 124/4885MAOA 1566/4885MAOB 1603/4885
US-20090318685-A1 METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF CA2, HAO2, KYAT1 CA9 110/4885MAOA 2348/4885MAOB 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.